Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub
505(b)(2) Hybrid Risperidone Long-Acting Injectable Given Name Uzedy
Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.
